Curex Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 29-06-2024
- Paid Up Capital ₹ 0.20 M
as on 29-06-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.23 M
as on 29-06-2024
- Revenue -51.64%
(FY 2022)
- Profit -76.07%
(FY 2022)
- Ebitda 1015.74%
(FY 2022)
- Net Worth 9.00%
(FY 2022)
- Total Assets -26.75%
(FY 2022)
About Curex Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹6.23 M.
Sarvesh Kumar and Ram Tiwari serve as directors at the Company.
- CIN/LLPIN
U33100DL2015PTC278835
- Company No.
278835
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Apr 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Curex Pharma Private Limited offer?
Curex Pharma Private Limited offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Antiseptic Liquid & Cream, Allopathic Cough Syrup, Zedex Syrup.
Who are the key members and board of directors at Curex Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sarvesh Kumar  | Director | 25-Apr-2022 | Current |
| Ram Tiwari | Director | 25-Apr-2022 | Current |
Financial Performance and Corporate Structure Insights of Curex Pharma.
Curex Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 51.64% decrease. The company also saw a substantial fall in profitability, with a 76.07% decrease in profit. The company's net worth moved up by a moderate rise of 9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curex Pharma?
In 2019, Curex Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Jul 2022 | ₹0.70 M | Open |
Others Creation Date: 01 Jun 2020 | ₹0.85 M | Open |
Others Creation Date: 20 Nov 2019 | ₹4.68 M | Open |
How Many Employees Work at Curex Pharma?
Unlock and access historical data on people associated with Curex Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
